Novartis has reported to make changes in the label of Gilenya

Novartis, Swiss drug manufacturer, has reported of making the changes to the label of its drug Fingolimod (Gilenya), medicine for

Read more

Chronic Obstructive Pulmonary Disease has gotten another foe

QVA149, trial medicine by Novartis for the treatment of chronic obstructive pulmonary disease (COPD), has achieved the required therapeutic targets

Read more

Cancer Cell Line Encyclopedia (CCLE) by Novartis and Broad Institute

Novartis has launched the Cancer Cell Line Encyclopedia (CCLE) to enlist the cancer cell lines in the world. This work

Read more

Novartis has reported its Q4 2011 results, showing decline in profit

Novartis AG, Swiss pharmaceuticals, has reported that the company’s profit may decline by 46% to $1.2 billion on charges in

Read more

Gilenya by Novartis is under review by European Medicines Agency

The European Medicines Agency said to doctors on Friday to have a check on patients for six hours after giving

Read more

Novartis Pharmaceuticals has planned to cut 1960 jobs in restructure

Novartis AG is restructuring its General medicines business in U.S. market to power up its position in the light of

Read more

Gilenya has been found effective against Multiple Sclerosis in Phase-III

Gilenya (fingolimod), an oral drug for the treatment of multiple sclerosis developed by Novartis, has achieved its main objective in

Read more

Two new auspicious therapeutic strategies against Breast Cancer

Two companies have raised a strong hope for the treatment of breast cancer. These companies are Roche and Novartis. Breast

Read more

Antimalarial drugs with double impact

Researchers have developed a new class of dual-action anti-malarial drugs that act on the liver as well as the blood

Read more
%d bloggers like this: